MD

SEC source: 0001209191-22-002411 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 839,450

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 25, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $26.99 to $27.63 for a weighted average sales price of $27.42. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-001141 · doc4.xml · nonDerivative · entry 2

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 852,089

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 25, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $27.19 to $27.93 for a weighted average sales price of $27.43. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-001141 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 939,450

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 25, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $27.03 to $27.36 for a weighted average sales price of $27.16. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-071616 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 946,014

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 25, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $26.96 to $27.64 for a weighted average sales price of $27.19. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-071507 · doc4.xml · nonDerivative · entry 3

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 991,411

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 25, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $26.98 to $27.43 for a weighted average sales price of $27.28. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-071507 · doc4.xml · nonDerivative · entry 2

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,016,411

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 25, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $27.15 to $27.71 for a weighted average sales price of $27.28. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-071507 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,060,925

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 25, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $26.84 to $27.48 for a weighted average sales price of $27.17. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-063836 · doc4.xml · nonDerivative · entry 1

Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,391

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted June 15, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $28.13 to $28.55 for a weighted average sales price of $28.38. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 62 shares acquired by reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing.

SEC source: 0001209191-21-063832 · doc4.xml · nonDerivative · entry 1

Pepia John C · CIK 0001674717 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,666

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 13, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $28.36 to $28.55 for a weighted average sales price of $28.45. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-062083 · doc4.xml · nonDerivative · entry 1

Pepia John C · CIK 0001674717 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,666

F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $26.83 to $26.94 for a weighted average sales price of $26.87. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes 61 shares acquired by the reporting person through the Issuer's Employee Stock Purchase Plan since the last Form 4 filing.

SEC source: 0001209191-21-062082 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,127,793

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 25, 2021.

SEC source: 0001209191-21-059844 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,138,180

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 25, 2021.

SEC source: 0001209191-21-054746 · doc4.xml · nonDerivative · entry 1

Pepia John C · CIK 0001674717 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,843

F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $31.63 to $31.92 for a weighted average sales price of $31.83. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes 58 shares acquired by the reporting person through the Issuer's Employee Stock Purchase Plan since the last Form 4 filed.

SEC source: 0001209191-21-054168 · doc4.xml · derivative · entry 3

ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 455,331

Underlying: Common Stock · 95,000 shares

Expires 2023-10-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date.

F3 · derivative.expiration_date: Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date.

SEC source: 0001209191-21-054168 · doc4.xml · nonDerivative · entry 2

ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,425

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $34.965 to $35.235 for a weighted average sales price of $35.09. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-054168 · doc4.xml · nonDerivative · entry 1

ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 303,425

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares acquired upon exercise of Stock Options granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan").

SEC source: 0001209191-21-050907 · doc4.xml · nonDerivative · entry 1

Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,129

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted June 15, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in thirty-six (36) separate transactions with prices ranging from $32.01 to $32.67 for an average weighted sale price of $32.35. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 128 shares acquired by the Reporting person through the Issuer's Employee Stock Purchase Plan since the last Form 4 filing.

SEC source: 0001209191-21-046555 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,139,450

F1 · kind: Represents 83,092 shares withheld for payment of taxes upon vesting of shares previously reported.

SEC source: 0001209191-21-045052 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,222,542

F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted August 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in eighty-seven (87) separate transactions with prices ranging from $30.08 to $30.53 for an average weighted sale price of $30.31. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-037166 · doc4.xml · nonDerivative · entry 1

Pepia John C · CIK 0001674717 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,785

F1 · kind: Represents 7,858 shares withheld for payment of taxes upon vesting of shares previously reported.

F2 · balance_after: Includes 70 shares acquired by reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing.

SEC source: 0001209191-21-032733 · doc4.xml · nonDerivative · entry 1

Weis Shirley A · CIK 0001623324 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,223

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-032727 · doc4.xml · nonDerivative · entry 1

Starcher John M. Jr. · CIK 0001583130 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,832

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-032724 · doc4.xml · nonDerivative · entry 1

SANSONE GUY P · CIK 0001301446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,516

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-032719 · doc4.xml · nonDerivative · entry 1

Rucker Michael A. · CIK 0001588247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,347

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-032716 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,322,542

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-032713 · doc4.xml · nonDerivative · entry 1

Kadre Manuel · CIK 0001396538 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,198

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-032715 · doc4.xml · nonDerivative · entry 1

McEachin Thomas · CIK 0001659781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,841

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-032709 · doc4.xml · nonDerivative · entry 1

GABOS PAUL G · CIK 0001216803 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,198

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-032707 · doc4.xml · nonDerivative · entry 1

WALDEMAR, MD CARLO A · CIK 0001218839 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,687

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-032703 · doc4.xml · nonDerivative · entry 1

Barker Karey D · CIK 0001641573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,663

F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.

SEC source: 0001209191-21-024762 · doc4.xml · nonDerivative · entry 2

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,317,657

F1 · kind: Sales made pursuant to Reporting Person's 10b5-1 trading plan.

SEC source: 0001209191-21-024762 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,318,439

F1 · kind: Sales made pursuant to Reporting Person's 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions with prices ranging from $24.80 to $25.80 for an average weighted sale price of $25.40. The reporting person undertakes to provide the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-016912 · doc4.xml · nonDerivative · entry 3

Pepia John C · CIK 0001674717 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,573

F3 · kind: Represents 2,568 shares withheld for payment of taxes upon vesting of shares previously reported.

F4 · balance_after: Includes 283 shares acquired by Reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing.

SEC source: 0001209191-21-016912 · doc4.xml · nonDerivative · entry 2

Pepia John C · CIK 0001674717 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,858

F2 · kind: Restricted shares granted pursuant to the Issuer's Plan, in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2022, twenty-five percent (25%) of the restricted shares will vest on March 1, 2023 and fifty percent (50%) of the restricted shares will vest on March 1, 2024.

SEC source: 0001209191-21-016912 · doc4.xml · nonDerivative · entry 1

Pepia John C · CIK 0001674717 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,653

F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 5,102 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2021. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five percent (25%) on March 1, 2022, twenty-five percent (25%) on March 1, 2023 and fifty percent (50%) on March 1, 2024, subject to the terms of the Plan.

SEC source: 0001209191-21-016905 · doc4.xml · nonDerivative · entry 2

Richards C Marc · CIK 0001468881 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,641

F2 · kind: Restricted shares granted pursuant to the Issuer's Plan, in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2022, twenty-five percent (25%) of the restricted shares will vest on March 1, 2023 and fifty percent (50%) of the restricted shares will vest on March 1, 2024.

SEC source: 0001209191-21-016905 · doc4.xml · nonDerivative · entry 1

Richards C Marc · CIK 0001468881 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,069

F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 14,286 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2021. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five (25%) on March 1, 2022, twenty-five (25%) on March 1, 2023 and fifty (50%) on March 1, 2024, subject to the terms of the Plan.

SEC source: 0001209191-21-016899 · doc4.xml · nonDerivative · entry 2

ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,425

F2 · kind: Restricted shares granted pursuant to the Issuer's Plan, in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2022, twenty-five percent (25%) of the restricted shares will vest on March 1, 2023 and fifty percent (50%) of the restricted shares will vest on March 1, 2024.

SEC source: 0001209191-21-016899 · doc4.xml · nonDerivative · entry 1

ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,996

F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 35,715 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2021. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five percent (25%) on March 1, 2022, twenty-five percent (25%) on March 1, 2023 and fifty percent (50%) on March 1, 2024, subject to the terms of the Plan.

SEC source: 0001209191-21-016895 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,417,657

F1 · kind: Represents 72,575 shares withheld for payment of taxes upon vesting of shares previously reported.

SEC source: 0001209191-21-016887 · doc4.xml · nonDerivative · entry 3

Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,800

F3 · kind: Represents 6,244 shares withheld for payment of taxes upon vesting of shares previously reported.

F4 · balance_after: Includes 182 shares acquired by Reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing.

SEC source: 0001209191-21-016887 · doc4.xml · nonDerivative · entry 2

Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,862

F2 · kind: Restricted shares granted pursuant to the Issuer's Plan, in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2022, twenty-five percent (25%) of the restricted shares will vest on March 1, 2023 and fifty percent (50%) of the restricted shares will vest on March 1, 2024.

SEC source: 0001209191-21-016887 · doc4.xml · nonDerivative · entry 1

Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,249

F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 15,306 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2021. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five (25%) on March 1, 2022, twenty-five (25%) on March 1, 2023 and fifty (50%) on March 1, 2024, subject to the terms of the Plan.

SEC source: 0001209191-21-016882 · doc4.xml · nonDerivative · entry 2

Andreano Dominic J · CIK 0001549694 · EVP, General Counsel and Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,497

F2 · kind: Restricted shares granted pursuant to the Issuer's Plan, in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2022, twenty-five percent (25%) of the restricted shares will vest on March 1, 2023 and fifty percent (50%) of the restricted shares will vest on March 1, 2024, subject to the terms of the Plan.

SEC source: 0001209191-21-016882 · doc4.xml · nonDerivative · entry 1

Andreano Dominic J · CIK 0001549694 · EVP, General Counsel and Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,945

F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 13,776 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2021. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five percent (25%) on March 1, 2022, twenty-five percent (25%) on March 1, 2023 and fifty percent (50%) on March 1, 2024, subject to the terms of the Plan.

SEC source: 0001209191-21-001146 · doc4.xml · nonDerivative · entry 2

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,490,232

F1 · kind: Sales made pursuant to Reporting Person's 10b5-1 trading plan adopted August 13, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in ninety-eight (98) separate transactions with prices ranging from $23.65 to $24.65 for an average weighted sale price of $23.89. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-001146 · doc4.xml · nonDerivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,543,193

F1 · kind: Sales made pursuant to Reporting Person's 10b5-1 trading plan adopted August 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in seventy-six (76) separate transactions with prices ranging from $23.15 to $23.645 for an average weighted sale price of $23.41. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-062948 · doc4.xml · nonDerivative · entry 4

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,590,232

F3 · kind: Sales made pursuant to Reporting Person's 10b5-1 trading plan adopted on August 13, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in twenty-seven (27) separate transactions with prices ranging from $23.00 to $23.15 for an average weighted sale price of $23.0439. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 5.

SEC source: 0001209191-20-062948 · doc4.xml · nonDerivative · entry 3

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,623,426

F3 · kind: Sales made pursuant to Reporting Person's 10b5-1 trading plan adopted on August 13, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in eight separate transactions with prices ranging from $23.00 to $23.04 for an average weighted sale price of $23.002. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 4.

SEC source: 0001209191-20-052356 · doc4.xml · derivative · entry 2

Andreano Dominic J · CIK 0001549694 · EVP, General Counsel and Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Common Stock · 96,000 shares

Expires 2023-12-26

F2 · derivative.exercise_date: Option to purchase shares of Common Stock awarded under the Plan that vests as follows: (A) 30,500 shares are exercisable if and when the Issuer's Common Stock price closes at $22 per share (or above) for any 40 consecutive trading days before the third anniversary of the grant date ("Performance End Date"); (B) 31,500 shares are exercisable if and when the Issuer's Common Stock closes at $25 per share (or above) for any 40 consecutive trading days before the Performance End Date; and (C) 34,000 shares are exercisable if and when the Issuer's Common Stock price closes at $29 (or above) for any 40 consecutive trading days before the Performance End Date, provided that no option shares will vest prior to the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Option to purchase shares of Common Stock awarded under the Plan that vests as follows: (A) 30,500 shares are exercisable if and when the Issuer's Common Stock price closes at $22 per share (or above) for any 40 consecutive trading days before the third anniversary of the grant date ("Performance End Date"); (B) 31,500 shares are exercisable if and when the Issuer's Common Stock closes at $25 per share (or above) for any 40 consecutive trading days before the Performance End Date; and (C) 34,000 shares are exercisable if and when the Issuer's Common Stock price closes at $29 (or above) for any 40 consecutive trading days before the Performance End Date, provided that no option shares will vest prior to the one-year anniversary of the grant date.